5,461 results match your criteria Inflammatory bowel diseases[Journal]


Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome.

Inflamm Bowel Dis 2019 Apr 16. Epub 2019 Apr 16.

Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz087DOI Listing
April 2019
4.464 Impact Factor

Informed Consent in IBD Trials: Where We Are and Where We Need to Go.

Inflamm Bowel Dis 2019 Apr 16. Epub 2019 Apr 16.

Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.

Patient enrollment is increasingly recognized as a major limiting factor to inflammatory bowel disease (IBD) clinical trial completion. Many IBD trials will fail to enroll enough patients to adequately power their study. This has led to a renewed multifaceted effort to encourage more patients to enroll in clinical trials. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz067DOI Listing
April 2019
1 Read

Increased Healthcare Utilization by Patients With Inflammatory Bowel Disease Covered by Medicaid at a Tertiary Care Center.

Inflamm Bowel Dis 2019 Apr 16. Epub 2019 Apr 16.

Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York, USA.

Background: Low socioeconomic status has been linked with numerous poor health outcomes, but data are limited regarding the impact of insurance status on inflammatory bowel disease (IBD) outcomes. We aimed to characterize utilization of healthcare resources by IBD patients based on health insurance status, using Medicaid enrollment as a proxy for low socioeconomic status.

Methods: We retrospectively identified adult patients with IBD engaged in a colorectal cancer surveillance colonoscopy program from July 2007 to June 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz060DOI Listing

Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology.

Inflamm Bowel Dis 2019 Apr 16. Epub 2019 Apr 16.

Northwestern University, Department of Medicine, Division of Gastroenterology and Hepatology, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz080DOI Listing

Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis.

Inflamm Bowel Dis 2019 Apr 13. Epub 2019 Apr 13.

Takeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.

Background: Inflammatory bowel disease (IBD) treatment in the elderly is challenging in part because of increased risk of infections. The aim of our study was to determine the absolute and relative risk of infections among the elderly IBD patient population and to identify factors affecting the risk of infections in the overall IBD patient population.

Methods: A retrospective study of patients with IBD initiating corticosteroids, immunomodulators (IM), or biologic therapy (January 2010-December 2014) was conducted using the Truven Market Scan database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz065DOI Listing
April 2019
1 Read

Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.

Inflamm Bowel Dis 2019 Apr 13. Epub 2019 Apr 13.

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.

Inflammatory bowel diseases are known for a chronic inflammatory process of the gastrointestinal tract and include Crohn's disease and ulcerative colitis (UC). Patients who are dependent on or resistant to corticosteroids account for about 20% of severe UC patients. Tacrolimus is a calcineurin inhibitor that has recently been used in the treatment of steroid-refractory ulcerative colitis. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz068DOI Listing
April 2019
1 Read

Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol.

Inflamm Bowel Dis 2019 Apr 13. Epub 2019 Apr 13.

Division of Gastroenterology, University of California, San Francisco, California, USA.

Background: Hospitalization for ulcerative colitis is a high-risk period associated with increased risk of Clostridium difficile infection, thromboembolism, and opiate use. The study aim was to develop and implement a quality-improvement intervention for inpatient ulcerative colitis management that standardizes gastroenterology consultant recommendations and improves delivery of evidence-based care.

Methods: All adult patients hospitalized for ulcerative colitis between July 1, 2014, and December 31, 2017, who received intravenous corticosteroids were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz066DOI Listing

Shiga Toxin Producing Escherichia coli-Hemolytic Uremic Syndrome Mimicking Acute Severe Ulcerative Colitis in a Child With Bloody Diarrhea.

Inflamm Bowel Dis 2019 04 1. Epub 2019 Apr 1.

NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant'Andrea University Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz058DOI Listing
April 2019
2 Reads

The Inflammatory Bowel Disease Medical Home: From Patients to Populations.

Inflamm Bowel Dis 2019 Apr 1. Epub 2019 Apr 1.

Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, Ohio.

With increasing emphasis on cost reduction and quality improvement, the transition to value-based care is underway. New models of health care delivery are being explored to optimize patient experience and outcomes while decreasing health care expenses. One such model is the specialty medical home (SMH), which provides multidisciplinary, high-quality care for chronic diseases with specialist involvement, such as inflammatory bowel disease (IBD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz062DOI Listing
April 2019
2 Reads

The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Apr 1. Epub 2019 Apr 1.

Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

The goals for treatment of inflammatory bowel diseases (IBDs) are changing from elimination of symptoms toward complete disease control-a process that demands both clinical and endoscopic remission. This new IBD treatment paradigm has been shifting from a conventional "step-up" approach toward a more "top-down" early intervention treatment strategy. Recent studies suggest that the use of biologic agents, specifically those targeting tumor necrosis factor alpha, earlier in the treatment course improves patient outcomes and can prevent progression to irreversible bowel damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz059DOI Listing
April 2019
1 Read

Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment.

Inflamm Bowel Dis 2019 Apr 1. Epub 2019 Apr 1.

Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China.

Background: Infliximab levels have been reported to be associated with mucosal healing (MH) in Crohn's disease (CD). However, whether the association differs between postinduction (week 14) and maintenance (week 30) has seldom been investigated. We aimed to analyze the association between serum infliximab trough levels and MH at the 2 different time points. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz061DOI Listing
April 2019
1 Read

Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.

Inflamm Bowel Dis 2019 Apr 1. Epub 2019 Apr 1.

Dep. of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerative colitis (UC) patients who failed infliximab (IFX). Although, a comparative efficacy evaluation of ADA and VDZ in this clinical setting is currently missing.

Aim: The aim of this study is to compare the efficacy of ADA and VDZ in patients affected by UC who failed IFX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz057DOI Listing

A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.

Inflamm Bowel Dis 2019 Mar 29. Epub 2019 Mar 29.

Inflammatory Bowel Disease Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.

Background: The aims of this study were to characterize the immune response profile in patients with Crohn's disease (CD) and early postoperative recurrence (POR), to identify predictive biomarkers, and to develop a noninvasive predictive tool for individual estimation of POR risk.

Methods: Sixty-one patients who had undergone ileocolonic resection for CD were prospectively included and followed up for 24 months. Fecal calprotectin (FC), analytical parameters, and plasma cytokines were obtained before surgery and at various time points during postoperative follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz053DOI Listing

The Relationship Between Adverse Childhood Experiences and Health Care Use in the Manitoba IBD Cohort Study.

Inflamm Bowel Dis 2019 Mar 23. Epub 2019 Mar 23.

From the University of Manitoba IBD Clinical and Research Centre.

Background: We aimed to determine the prevalence of adverse childhood experiences (ACEs) in persons with inflammatory bowel disease (IBD) and whether having ACEs was associated with health care utilization post-IBD diagnosis.

Method: Three hundred forty-five participants from the population-based Manitoba IBD Cohort Study self-reported ACEs (ie, physical abuse, sexual abuse, death of a very close friend or family member, severe illness or injury, upheaval between parents, and any other experience thought to significantly impacts one's life or personality) at a median of 5.3 years following IBD diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz054DOI Listing
March 2019
1 Read

The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application.

Inflamm Bowel Dis 2019 Mar 27. Epub 2019 Mar 27.

Department of Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.

Objectives: Existing measures of inflammatory bowel disease (IBD) symptoms are not well suited to self-report, inadequate in measurement properties, insufficiently specific, or burdensome for brief or repeated administration. We aimed to develop a patient-reported outcome measure to assess a broader range of IBD symptoms.

Methods: The IBD Symptoms Inventory (IBDSI) was developed by adapting symptom items from existing clinician-rated or diary-format inventories; after factor analysis, 38 items were retained on 5 subscales: bowel symptoms, abdominal discomfort, fatigue, bowel complications, and systemic complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz038DOI Listing
March 2019
1 Read

Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Mar 27. Epub 2019 Mar 27.

Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly identified in patients with inflammatory bowel disease (IBD), but there are few systematic reviews and meta-analyses of the studies of NAFLD in IBD patients.

Methods: MEDLINE, Web of Science, Cochrane Library, and Scopus were searched (until August 2018) to identify observational studies that reported the prevalence and risk factors for NAFLD in IBD patients. Pooled prevalence, odds ratios (OR), mean difference (MD), and 95% confidence intervals (95% CI) were calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz043DOI Listing
March 2019
1 Read

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells' Differentiation and Function in Induction of Colitis.

Inflamm Bowel Dis 2019 Mar 27. Epub 2019 Mar 27.

Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas.

Background: How the gut microbiota regulates intestinal homeostasis is not completely clear. Gut microbiota metabolite short-chain fatty acids (SCFAs) have been reported to regulate T-cell differentiation. However, the mechanisms underlying SCFA regulation of T-cell differentiation and function remain to be investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz046DOI Listing
March 2019
2 Reads

Intestinal CD103+CD4+ and CD103+CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up.

Inflamm Bowel Dis 2019 Mar 27. Epub 2019 Mar 27.

Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, the Netherlands.

Background: The integrin CD103 is proposed to be a potential therapeutical target in inflammatory bowel disease (IBD), as it can form a heterodimeric integrin with β7 (Etrolizumab, anti-β7 integrin) on epithelial T cells. Therefore, we aimed to study the frequencies of different intestinal CD103+T-cell subsets, both CD4+ and CD8+, in newly diagnosed, untreated IBD patients at baseline and during follow-up, compared with healthy controls.

Methods: Intestinal biopsies from inflamed segments during colonoscopy and peripheral blood samples were prospectively taken from IBD patients at diagnosis and during follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz049DOI Listing
March 2019
5 Reads

Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers.

Inflamm Bowel Dis 2019 Mar 27. Epub 2019 Mar 27.

Sachs' Children and Youth Hospital, South General Hospital, Stockholm, Sweden.

Background: Childhood-onset inflammatory bowel disease (IBD) might negatively impact academic school performance. We conducted a nationwide study to examine the association between childhood-onset IBD and school results.

Methods: Our study population was selected from Swedish health registers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz040DOI Listing
March 2019
1 Read

Vedolizumab-Induced Remission in 3 Patients With Refractory Microscopic Colitis: A Tertiary Care Center Case Series.

Inflamm Bowel Dis 2019 Mar 19. Epub 2019 Mar 19.

Department of Gastroenterology, Johns Hopkins School of Medicine, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz042DOI Listing

The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded Protein Response Sensor PERK.

Inflamm Bowel Dis 2019 Mar 19. Epub 2019 Mar 19.

School of Applied Sciences, Edinburgh Napier University, Sighthill Campus, Sighthill Court, Edinburgh, Scotland.

Background: Genetic studies have strongly linked autophagy to Crohn's disease (CD), and stimulating autophagy in CD patients may be therapeutically beneficial. The aim of this study was to evaluate the effect of current inflammatory bowel disease (IBD) drugs on autophagy and investigate molecular mechanisms of action and functional outcomes in relation to this cellular process.

Methods: Autophagy marker LC3 was evaluated by confocal fluorescence microscopy and flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz039DOI Listing
March 2019
2 Reads

The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Mar 19. Epub 2019 Mar 19.

Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Background: Inflammatory bowel disease (IBD) is associated with a high prevalence of comorbid depressive and anxiety disorders. A significant proportion of IBD patients with comorbid psychiatric disorders remain undiagnosed and untreated, but factors associated with diagnosis are unknown. We evaluated the prevalence of undiagnosed depression and anxiety in an IBD cohort, along with the associated demographic and clinical characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz045DOI Listing
March 2019
1 Read

Reply to "Transient Elastography in IBD Patients".

Inflamm Bowel Dis 2019 Mar 19. Epub 2019 Mar 19.

Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz048DOI Listing

Transient Elastography in IBD Patients.

Inflamm Bowel Dis 2019 Mar 19. Epub 2019 Mar 19.

Department of Gastroenterology and Hepatology, Christchurch Hospital, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz047DOI Listing

Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small Bowel Crohn's Disease and its Complications.

Inflamm Bowel Dis 2019 Mar 19. Epub 2019 Mar 19.

Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.

Background: In patients with inflammatory bowel disease, we strive to achieve mucosal healing, as this has been shown to decrease the risk of disease flares, hospitalization, and surgery. For this reason, we must use objective measures of mucosal healing to inform our clinical decision-making and can no longer rely on patient symptoms alone. Assessment of small bowel Crohn's disease (SBCD) is particularly challenging given its lack of accessibility via standard endoscopic techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy392DOI Listing
March 2019
1 Read

Confocal Laser Endomicroscopy in the Evaluation of Inflammatory Bowel Disease.

Authors:
Anna M Buchner

Inflamm Bowel Dis 2019 Mar 16. Epub 2019 Mar 16.

Division of Gastroenterology at University of Pennsylvania, Philadelphia, Pennsylvania.

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, can be effectively monitored with the use of endoscopy. The additional application of small field imaging technology such as confocal laser endomicroscopy CLE during ongoing endoscopic evaluation has led to real-time visualization of mucosal abnormalities and thus in vivo histology. The endomicroscopy (CLE) can improve IBD endoscopic evaluation by identifying seemingly normal-appearing mucosa, assessing the function of the intestinal barrier of the epithelium and vascular permeability, and by characterizing any mucosal lesions, including dysplastic lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz021DOI Listing
March 2019
1 Read

Contraception, Venous Thromboembolism, and Inflammatory Bowel Disease: What Clinicians (and Patients) Should Know.

Inflamm Bowel Dis 2019 Mar 16. Epub 2019 Mar 16.

Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts.

The peak incidence of the inflammatory bowel diseases (IBDs) is between the second and fourth decades of life, which coincides with prime reproductive years. Unplanned or mistimed pregnancies may account for nearly half of all pregnancies and are associated with adverse consequences such as a higher risk of delayed preconceptual care, increased risk of preterm birth, low birth weight, and adverse maternal and neonatal outcomes. Increased IBD activity during pregnancy is also associated with adverse pregnancy-related outcomes, such as miscarriage, intrauterine growth retardation, and preterm birth. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz025DOI Listing
March 2019
7 Reads
4.464 Impact Factor

Shall Patients With a History of Inflammatory Bowel Disease-Related Surgery Be Excluded in the Assessment of Sexual Function?

Authors:
Yun Li Xiaowei Liu

Inflamm Bowel Dis 2019 Mar 15. Epub 2019 Mar 15.

Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Surgical treatment is not rare for patients with IBD. Currently, surgery seems to have a protective effect on sexual function. Thus, exclusion of those treated with IBD related surgery may affect conclusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz026DOI Listing
March 2019
1 Read

Smoking and Risk of Microscopic Colitis: A Systematic Review and Meta-analysis.

Inflamm Bowel Dis 2019 Mar;25(4):672-678

Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Background: The association between smoking and inflammatory bowel disease has long been recognized, but its role in the development of microscopic colitis is less well defined. This systematic review and meta-analysis was conducted with the aims to identify all available studies on the association between smoking and risk of microscopic colitis and to synthesize their results.

Methods: The MEDLINE and EMBASE databases were searched from inception to May 2018 for cohort studies and case-control studies that compared the risk of microscopic colitis among current/former smokers vs individuals who have never smoked. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy296DOI Listing

A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab.

Inflamm Bowel Dis 2019 Mar 13. Epub 2019 Mar 13.

Lahey Hospital & Medical Center, Tufts Medical School, Burlington Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz033DOI Listing

Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Mar 11. Epub 2019 Mar 11.

Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Background And Aims: Cross-sectional studies on sexual function in men with inflammatory bowel disease (IBD) yield mixed results. Using a prospective incidence cohort, we aimed to describe sexual function at baseline and over time and to identify factors associated with impaired sexual function in men with IBD.

Methods: Men 18 years and older enrolled between April 2008 and January 2013 in the Ocean State Crohn's and Colitis Area Registry (OSCCAR) with a minimum of 2 years of follow-up were eligible for study. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy401DOI Listing
March 2019
14 Reads

Eosinophils in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Mar 11. Epub 2019 Mar 11.

College of Health and Biomedicine, Institute for Health and Sport, Victoria University, Melbourne, Australia.

Clinical investigations in inflammatory bowel disease (IBD) patients have provided increasing evidence that eosinophils contribute to chronic intestinal inflammation. Accumulation of eosinophils in the gastrointestinal tract correlates with the variations of eosinophil regulatory molecules; however, their role in gastrointestinal dysfunction in IBD has not been fully elucidated. This review will describe the development and characterization of gastrointestinal eosinophils, mechanisms of eosinophil recruitment to the gastrointestinal tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz024DOI Listing
March 2019
2 Reads

Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Mar 10. Epub 2019 Mar 10.

Icahn Institute for Genomics & Multiscale Biology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York NY, USA.

Background: Recurrent and severe Clostridium difficile infections (CDI) are treated with fecal microbiota transplant (FMT). Uncertainty exists regarding FMT effectiveness for CDI with underlying inflammatory bowel disease (IBD) and regarding its effects on disease activity and effectiveness in transferring the donor microbiota to patients with and without IBD.

Methods: Subjects with and without IBD who underwent FMT for recurrent or severe CDI between 2013 and 2016 at The Mount Sinai Hospital were followed for up to 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy398DOI Listing
March 2019
2 Reads
4.464 Impact Factor

Reply to Comment on "Inflammatory Bowel Diseases Were Associated With Risk of Sexual Dysfunction in Both Sexes: A Meta-analysis" by Li Y and Liu X.

Inflamm Bowel Dis 2019 Mar 9. Epub 2019 Mar 9.

Department of Urology & Andrology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz028DOI Listing

Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients.

Inflamm Bowel Dis 2019 Mar 7. Epub 2019 Mar 7.

Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Background: Post-traumatic stress (PTS), or the psycho-physiological response to a traumatic or life-threatening event, is implicated in medical patient outcomes. Emerging evidence suggests a complex relationship between PTS, the brain-gut axis, the gut microbiome, and immune function. Inflammatory bowel disease (IBD) may be susceptible to PTS and its subsequent impacts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz032DOI Listing
March 2019
2 Reads

Author's Reply to Drs. Franco Scaldaferri and Valentina Petito, PhDs.

Inflamm Bowel Dis 2019 Mar 6. Epub 2019 Mar 6.

Division of Gastroenterology, Hepatology and Nutrition Children's Mercy Hospital, Kansas City, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz029DOI Listing
March 2019
6 Reads

Commentary to "Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease".

Inflamm Bowel Dis 2019 Mar 6. Epub 2019 Mar 6.

Università Cattolica del Sacro Cuore, Istituto di Patologia Speciale Medica, Roma, Italia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz031DOI Listing
March 2019
1 Read

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.

Inflamm Bowel Dis 2019 Mar 6. Epub 2019 Mar 6.

Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida, USA.

Background And Aims: Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD).

Methods: Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz001DOI Listing
March 2019
2 Reads

Antidepressants in IBD: Healthy Adherer Effect?

Inflamm Bowel Dis 2019 Mar 6. Epub 2019 Mar 6.

Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz036DOI Listing
March 2019
3 Reads

Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis.

Inflamm Bowel Dis 2019 Mar 6. Epub 2019 Mar 6.

Department of Gastroenterology, Johns Hopkins School of Medicine, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz027DOI Listing
March 2019
2 Reads

Response to Letter by Moulton et al.

Inflamm Bowel Dis 2019 Mar 2. Epub 2019 Mar 2.

Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz035DOI Listing
March 2019
1 Read

Out of Sight, Out of Mind: The Limitations of the Hospital Anxiety and Depression Scale in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Mar 2. Epub 2019 Mar 2.

Centre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz034DOI Listing
March 2019
2 Reads

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.

Inflamm Bowel Dis 2019 Feb 27. Epub 2019 Feb 27.

Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, Missouri, USA.

Background And Aims: Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn's disease (CD) of the pouch and chronic antibiotic-dependent or antibiotic-refractory pouchitis.

Methods: This was a retrospective, multicenter cohort study at 5 academic referral centers in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz030DOI Listing
February 2019
3 Reads
4.464 Impact Factor

The Unsolved Link of Genetic Markers and Crohn's Disease Progression: A North American Cohort Experience.

Inflamm Bowel Dis 2019 Feb 25. Epub 2019 Feb 25.

Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Group, Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada.

Background: While progress has been made in the identification of Crohn's disease (CD) susceptibility loci, efforts to identify a genetic basis for disease progression have been less fruitful. The specific aim of this study was to build upon the major genetic advances made in IBD by applying genome-wide technologies toward predicting disease progression in CD.

Methods: Crohn's disease cases (n = 1495) from 3 IBD centers were reviewed by experienced physicians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz016DOI Listing
February 2019
7 Reads

Streptococcus Salivarius: A Potential Salivary Biomarker for Orofacial Granulomatosis and Crohn's Disease?

Inflamm Bowel Dis 2019 Feb 23. Epub 2019 Feb 23.

Department of Medical and Molecular Genetics, Faculty of Life Science and Medicine, King's College London, London, United Kingdom.

Background: Orofacial granulomatosis (OFG) is a rare disease characterised by chronic, noncaseating, granulomatous inflammation primarily affecting the oral cavity. Histologically, it is similar to Crohn's disease (CD), and a proportion of patients have both OFG and CD. The cause of OFG remains elusive, but it has been suggested that microbial interactions may be involved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz022DOI Listing
February 2019
6 Reads

Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Increasing uptake of biologic therapy has contributed to declining surgical rates for inflammatory bowel disease (IBD). However, a significant number of patients on biologic therapy will go on to require surgery. The literature is conflicted with regard to the preoperative management of biologic therapy before urgent or elective IBD surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz002DOI Listing
February 2019

Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No. 1 Shuaifuyuan, Beijing, China.

Background: Carcinogenesis is a severe consequence of chronic ulcerative colitis. We investigated the somatic mutations and pathway alterations in ulcerative colitis-associated colorectal cancer (CRC) in Chinese patients compared with sporadic CRCs to reveal potential therapeutic targets in ulcerative colitis-associated CRC.

Methods: Whole exome sequencing was performed on archival tumor tissues and paired adjacent nondysplastic mucosa from 10 ulcerative colitis-associated CRC patients at a high risk of carcinogenesis. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz020DOI Listing
February 2019
9 Reads